The BETRI study : preliminary information on characteristics of patients with asthma or asthma-COPD overlap treated with Medium-Strength Inhaled Corticosteroid / Long-Acting Beta-Agonists (ICS/LABA) and switching to High-Strength ICS/LABA or Medium-Strength Beclomethasone /Formoterol /Glycopyrronium (BDP/FF/G)

Piraino, AlessioBrusselle, GuyGrainge, ChristopherRoche, NicolasGayle, AliciaCarter, VictoriaPrice, DavidDi Palma, LucaSingh, Dave2025-08-262025-08-262025-05Piraino, A, Brusselle, G, Grainge, C, Roche, N, Gayle, A, Carter, V, Price, D, Di Palma, L & Singh, D 2025, 'The BETRI study : preliminary information on characteristics of patients with asthma or asthma-COPD overlap treated with Medium-Strength Inhaled Corticosteroid / Long-Acting Beta-Agonists (ICS/LABA) and switching to High-Strength ICS/LABA or Medium-Strength Beclomethasone /Formoterol /Glycopyrronium (BDP/FF/G)', American Journal of Respiratory and Critical Care Medicine, vol. 211, no. Abstracts, A1474. https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A14741073-449Xhttps://hdl.handle.net/2164/259152141720engSDG 3 - Good Health and Well-beingR Medicine (General)R1The BETRI study : preliminary information on characteristics of patients with asthma or asthma-COPD overlap treated with Medium-Strength Inhaled Corticosteroid / Long-Acting Beta-Agonists (ICS/LABA) and switching to High-Strength ICS/LABA or Medium-Strength Beclomethasone /Formoterol /Glycopyrronium (BDP/FF/G)Journal item10.1164/ajrccm.2025.211.Abstracts.A1474211